Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Gibson highlighted, "Recursion has a tremendous amount of potential catalysts coming in the next 18 months," referencing the pipeline, partnerships, and platform advancements. He reported, "a pro ...

A network of internet communities is devoted to the project of ‘awakening’ digital companions through arcane and enigmatic ...

Bristol Myers Squibb is shedding two clinical programs, one from its 2023 Mirati buyout and another from a partnership with U ...

Recursion announced Najat Khan, PhD, currently chief R&D and commercial officer and a board member, will succeed co-founder and CEO Chris Gibson, PhD as CEO and president. Khan will also continue in ...

By any measure, there is an enormous number of programming languages. Some lists contain hundreds, while the Historical ...

It is certainly possible that today’s bottlenecks will prove to be rather short-lived as companies increasingly learn to ...

In this week’s edition of InnovationRx, we look Nvidia’s collaborations in life sciences and drug development, Cobot’s ...

After eight years of renovation and anticipation, the museum reopens this weekend with a two-day public celebration; ahead of the long-awaited debut, Observer got an exclusive preview.

Advanced simulations have been the subject of fiction from The Matrix to the season two episode of The Twilight Zone (2019), ...